News und Analysen
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler: Successful fiscal year 2022
EQS-News: Eckert & Ziegler: Successful fiscal year 2022
EQS-News: Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)
EQS-News: Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)
EQS-News: Eckert & Ziegler with Unchanged Dividend Proposal
EQS-News: Eckert & Ziegler with Unchanged Dividend Proposal
EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
EQS-News: Change in the Supervisory Board of Eckert & Ziegler AG
EQS-News: Change in the Supervisory Board of Eckert & Ziegler AG
EQS-Adhoc: Changes in the Management Board of Eckert & Ziegler
EQS-Adhoc: Changes in the Management Board of Eckert & Ziegler
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-News: Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
EQS-News: Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
DGAP-News: Eckert & Ziegler with Successful First Half of 2022
DGAP-News: Eckert & Ziegler with Successful First Half of 2022
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
DGAP-News: Eckert & Ziegler with Sales Growth in the First Quarter of 2022
DGAP-News: Eckert & Ziegler with Sales Growth in the First Quarter of 2022